Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Momenta’s Generic Lovenox Suit Is Harbinger Of Biosimilar Battles Over Manufacturing

You may also be interested in...

FDA Hit With Slew Of Suits As Firms Fight For Market Advantage

At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.

Manufacturing Patents In Peril After Court Extends Hatch-Waxman “Safe Harbor”

In a dispute related to Amphastar/Watson’s generic enoxaparin, a Federal Circuit panel takes an expansive view of the “Bolar Amendment” and finds that certain post-approval activities are protected from infringement claims, including quality control batch testing of commercial product. The decision draws a blistering dissent from the appeals court’s chief judge, who warns the ruling will “render manufacturing method patents worthless.”

Biosimilars Guidances To Focus On Naming, Tracking, Defining “Protein”

Without offering a timeline for release, CDER’s Rachel Sherman says the documents will also address exclusivity issues, as well as specifying what constitutes “publicly available” information regarding FDA’s previous determination of safety, purity and potency.

Related Content

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts